Literature DB >> 32384539

Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry.

Guillaume Moulis1,2,3, Thibault Comont4, Johanne Germain1, Agnès Sommet1,2,5, Maryse Lapeyre-Mestre1,2,5, Odile Beyne-Rauzy4, Daniel Adoue4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32384539      PMCID： PMC7218411          DOI： 10.1182/bloodadvances.2020001664

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  15 in total

1.  Range of antinuclear antibodies in "healthy" individuals.

Authors:  E M Tan; T E Feltkamp; J S Smolen; B Butcher; R Dawkins; M J Fritzler; T Gordon; J A Hardin; J R Kalden; R G Lahita; R N Maini; J S McDougal; N F Rothfield; R J Smeenk; Y Takasaki; A Wiik; M R Wilson; J A Koziol
Journal:  Arthritis Rheum       Date:  1997-09

2.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 3.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

4.  Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.

Authors:  Guillaume Moulis; Johanne Germain; Thibault Comont; Natacha Brun; Claire Dingremont; Brice Castel; Sophie Arista; Laurent Sailler; Maryse Lapeyre-Mestre; Odile Beyne-Rauzy; Bertrand Godeau; Daniel Adoue
Journal:  Am J Hematol       Date:  2017-03-20       Impact factor: 10.047

5.  Screening for autoimmune markers is unnecessary during follow-up of adults with autoimmune thrombocytopenic purpura and no autoimmune markers at onset.

Authors:  J M Vantelon; B Godeau; C André; P Bierling
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

6.  Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.

Authors:  Marie A Hollenhorst; Hanny Al-Samkari; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

7.  Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura.

Authors:  Abdullah Altintas; Abdulkadir Ozel; Nilufer Okur; Nurettin Okur; Timucin Cil; Semir Pasa; Orhan Ayyildiz
Journal:  J Thromb Thrombolysis       Date:  2007-04-14       Impact factor: 2.300

8.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

9.  Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France.

Authors:  Guillaume Moulis; Aurore Palmaro; Jean-Louis Montastruc; Bertrand Godeau; Maryse Lapeyre-Mestre; Laurent Sailler
Journal:  Blood       Date:  2014-10-10       Impact factor: 22.113

10.  A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura.

Authors:  Salah Yousef Abbasi; Mohammed Milhem; Luna Zaru
Journal:  Ann Hematol       Date:  2008-02-12       Impact factor: 3.673
View more
  2 in total

1.  Real-world Experience of Rituximab in Immune Thrombocytopenia.

Authors:  Kundan Mishra; Suman Kumar; Aditya Jandial; Kamal Kant Sahu; Rajeev Sandal; Ankur Ahuja; Sanjeev Khera; Yanamandra Uday; Rajiv Kumar; Rajan Kapoor; Tarun Verma; Sanjeevan Sharma; Jasjit Singh; Satyaranjan Das; Tathagat Chatterjee; Ajay Sharma; Velu Nair
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-01       Impact factor: 0.915

2.  Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?

Authors:  Mehmet Baysal; Volkan Baş; Elif Ümit; Hakkı Onur Kırkızlar; Ahmet Muzaffer Demir
Journal:  Turk J Haematol       Date:  2021-06-24       Impact factor: 1.831
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.